Treatment of sleep apnoea early after myocardial infarction with adaptive servo-ventilation: a proof-of-concept randomised controlled trial

Arzt, Michael and Fox, Henrik and Stadler, Stefan and Hetzenecker, Andrea and Oldenburg, Olaf and Hamer, Okka W. and Poschenrieder, Florian and Wiest, Clemens and Tanacli, Radu and Kelle, Sebastian and Bruch, Leonhard and Seidel, Mirko and Koller, Michael and Zeman, Florian and Buchner, Stefan (2024) Treatment of sleep apnoea early after myocardial infarction with adaptive servo-ventilation: a proof-of-concept randomised controlled trial. EUROPEAN RESPIRATORY JOURNAL, 64 (3): 2302338. ISSN 0903-1936, 1399-3003

Full text not available from this repository. (Request a copy)

Abstract

Background: Sleep disordered breathing (SDB) has been associated with less myocardial salvage and smaller infarct size reduction after acute myocardial infarction (AMI). The Treatment of sleep apnoea Early After Myocardial infarction with Adaptive Servo-Ventilation (TEAM-ASV I) trial investigated the effects of adding adaptive servo-ventilation (ASV) for SDB to standard therapy on the myocardial salvage index (MSI) and change in infarct size within 12 weeks after AMI. Methods: In this multicentre, randomised, open-label trial, patients with AMI and successful percutaneous coronary intervention within 24 h after symptom onset plus SDB (apnoea-hypopnoea index >= 15 events<middle dot>h(-1)) were randomised to standard medical therapy alone (control) or plus ASV (starting 3.6 +/- 1.4 days post-AMI). The primary outcome was the MSI at 12 weeks post-AMI. Cardiac magnetic resonance (CMR) imaging was performed at <= 5 days and 12 weeks after AMI. Results: 76 individuals were enrolled from February 2014 to August 2020; 39 had complete CMR data for analysis of the primary end-point. The MSI was significantly higher in the ASV versus control group (difference 14.6% (95% CI 0.14-29.1%); p=0.048). At 12 weeks, absolute (6.6 (95% CI 4.8-8.5) versus 2.8 (95% CI 0.9-4.8) % of left ventricular mass; p=0.003) and relative (44 (95% CI 30-57) versus 21 (95% CI 6-35) % of baseline; p=0.013) reductions in infarct size were greater in the ASV versus control group. No serious treatment-related adverse events occurred. Conclusions: Early treatment of SDB with ASV improved the MSI and decreased infarct size at 12 weeks after AMI. Larger randomised trials are required to confirm these findings.

Item Type: Article
Uncontrolled Keywords: RISK SCORE CALCULATOR; PULMONARY-HYPERTENSION; CARDIAC-OUTPUT;
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin II
Medicine > Lehrstuhl für Röntgendiagnostik
Medicine > Zentren des Universitätsklinikums Regensburg > Zentrum für Klinische Studien
Depositing User: Dr. Gernot Deinzer
Date Deposited: 15 Sep 2025 09:18
Last Modified: 15 Sep 2025 09:18
URI: https://pred.uni-regensburg.de/id/eprint/64216

Actions (login required)

View Item View Item